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Malignant melanoma (MM) is a common cancer among
Caucasians and has shown a deplorable increase in incidence rates
during recent decades. Early diagnosis – and consequently early
surgical excision – has been greatly improved, leading to an
average 5-year survival rate of up to 80%. Therefore, stable inci-
dent death rates of MM could be observed. However, the prog-
nosis of metastatic MM still remains poor, with a long-term
survival rate of about 20% in stage III patients (Balch et al, 1992;
Johnson et al, 1995).
Cytogenetic analyses of cell lines derived from MM have been
reported for more than 20 years (Chen et al, 1973). The data
obtained are quite complex and not always unambiguous.
However, the non-random involvement of chromosomes 1, 6, 7
and 9 has been published repeatedly (Chen et al, 1973; Koprowski
et al, 1985; Heim et al, 1988; Trent at al, 1990; Balch et al, 1992).
Deletions or loss of function of the p53 tumour-suppressor gene
(p53-TSG) have been found in roughly 50% of all malignant
tumours (Kamb et al, 1994). Mutations of the p53-TSG have been
found to be characteristic for carcinogenes and biochemical mech-
anisms responsible for genetic lesions in DNA that cause cancer
(Harris et al, 1993). Loss of function of p53 has been reported for
colon, oesophageal squamous cell, pancreatic and hepatic carci-
noma and other malignant tumours of the brain, lung, breast and
ovary (Levine, 1993). Despite numerous studies, no clear informa-
tion on the role of p53 in MM is available to date (Stretch et al,
1991; Akslen et al, 1992; Catresana et al, 1993; Piepkorn, 1994;
Kanoko et al, 1995; Poremba et al, 1995; Saez-Santamaría et al,
1995; Talve et al, 1996). The majority of cultured MM cell lines is
described to express p53 protein as assessed by monoclonal anti-
body binding. Point mutations in the p53 coding sequence (usually
cytosine to thymidine) have been found in 30% of cases (Piepkorn,
1994). Stretch et al report that 73% of primary and 93% of
metastatic melanomas express mutant p53 protein (Stretch et al,
1991). However, there are also reports describing a reduced p53
expression in metastatic MM compared with primary lesions
(Catresana et al, 1993).
To investigate the role of p53-TSG in metastatic MM, we
analysed 11 metastatic MM derived from 11 patients cytogeneti-
cally by chromosome banding techniques and FISH after short-
term culture. In addition, paraffin-embedded tissues of 9 of the 11
MM were examined immunohistochemically using DO-7, an anti-
body reacting with both wild-type and mutant p53 protein.
MATERIAL AND METHODS
Material
Eleven surgically removed, histologically confirmed metastatic
MM (ME 1 to ME 11) from 11 patients were minced with scissors
and prepared for short-term culture by standard methods
(Pederson et al, 1986). Patients’ data are briefly described in Table
1. For preparing MM specimens for cytogenetic investigation,
collagenase (Worthington Biochemical Corporation, NJ, USA)
200 U ml–1 was used over night.
The next day, cells were washed three times to start cultivation in
a collagenase-free medium with RPMI-1640 medium (Sera-lab,
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fetal calf serum (FCS) (Gibco BRL, Life Technologies, NY, USA),
1% AB-AM-solution (10 000 U ml–1 Penicillin-G-Sodium, 10 000
mg ml–1 streptomycin-sulfate, 25 mg ml–1 amphotericin-B in 0.85%
sodium chloride solution, Gibco BRL), 1% L-glutamine (Gibco
BRL), 1% sodium-pyruvate (JRM Biosciences), Geneticin (Gibco
BRL) 100 mg ml–1. Cells were cultured for 2–72 h to avoid in vitro
artefacts. Metaphase cells were prepared according to standard tech-
niques using colcemid 0.5 mg ml–1 treatment, hypotonic shock in
0.075 M potassium chloride and fixation in a 3:1 mixture of
methanol and glacial acetic acid (Pederson et al, 1986; Drach, 1994).
Karyotype analysis
The following banding techniques were used: Q-banding with
quinacrine and R-banding with acridine orange for ME 1, 2, 4 and
5 after denaturation in phosphate buffer. ME 7, 8, 10 and 11 were
R-C-banded using chromomycin, distamycin and DAPI (4¢–6¢-
diamidino-2-phenylindole-2HCl) as described (Schweitzer et al,
1994). The karyotypes were classified according to ISCN 1995
(Mitelman, 1995).
FISH
For our investigation, two probes were used simultaneously in a
dual-colour FISH assay: an a-satellite DNA probe specific for the
centromeric region of chromosome 17 (labelled with spectrum-
green) and a probe specific for the locus 17p13.1 (labelled with spec-
trum-orange). Both probes were purchased from Vysis (Vysis LSI
p53 DNA probe; Vysis, Stuttgart, Germany). FISH of interphase
nuclei was performed as previously described (Drach et al, 1995).
For prehybridization, slides were immersed in 0.1 N
hydrochloric acid/0.05% Triton-X-100, washed twice in saline
sodium citrate (SSC) and ethanol (100%). DNA was denatured by
incubation with formamide (70% in 2 ´ SSC) at 70°C for 5 min.
Cells were again dehydrated using ethanol. The hybridization
mixture (10 ml) was then applied to each slide. The slides were
coverslipped and sealed with rubber cement. The hybridization
solution contained formamide (65%; Sigma, St Louis, MO, USA),
2´ SSC, dextran sulphate (10%, Oncor, Gaithersburg, MD, USA),
salmon sperm DNA (100 mg ml–1; Sigma), and the specific probes
(2 mg ml–1 final concentration). Hybridization was performed
overnight at 37°C in a humidified chamber. Post-hybridization
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Table 1 Patients’ data and clinical information of the patients as far as available
Case Initials Sex PM Localization of Date and localization of metastases Prior
PM treatment
ME 1 DP M 1990: PM of Right cheek 1991: cervical LN, right parotis DTIC
7.3 .'41 unknown type 1992: ing and perianal LN carboplatin
1994: multiple sc metastases DTIC/
1994: liver, kidney, peritoneum, lung, muphoran
mediastinum
11. 1994: right tibia
ME 2 ZE F 1991: NMM Trunk 12. 1993 + 9. 1994: left axillary LN DTIC
1.9.'46 C IV, B 2 mm 9. 1994: trunk, sc Intron A
12. 1994: trunk, sc IFN-a
12. 1994: lung
ME 3 BE F 1993: NMM Unknown 4. 1995: left ing LN –
27.5.'34 C IV, B 1, 96 mm
ME 4 PH F 1953: PM of Right calf 5. 1995: right ing LN –
20.3.'14 unknown type
ME 5 SF M Unknown Unknown 8. 1995: trunk, sc –
8.10.'20
ME 6 LO M 10. 1994: Left calf 6. 1995: left ing LN –
9.7.'12 C III, B 2, 7 mm
ME 7 RF M 1989: NMM Reg scapularis 9. 1995: right axillary LN –
23.10.'37 C IV, B 1, 97 mm dex
ME 8 BK M Unknown Unknown 9. 1995: left axillary LN –
2.9.'35
ME 9 DA M 1993: SSM Left ear 10. 1995: LN at parotic gland –
9.5.'27
ME 10 NA M 1987: C IV, Left calf 4. 1995: left ing LN –
16.2.'31 B 1, 96 mm
ME 11 SF M 10. 1995: PM of Right shoulder 11. 1995: right axillary LN –
5.9.'24 unknown type
Date and localization of the investigated specimens are in bold. Birthdates of the patients are presented under their initials. B, Breslow; C, Clark; DTIC,
dacarbazine; IFN-a; interferon alpha; LN, lymph node; NMM, nodular malignant melanoma; PM, primary melanoma; sc, subcutaneous; SSM, superficially
spreading melanoma; ing, inguinal.washes consisted of three rinses in 50% formamide/2 ´ SSC at
45°C and two rinses in 2 ´ SSC at 37°C. Finally, nuclei were
counterstained with DAPI. Cells were analysed under a fluores-
cence microscope (Olympus AH.3 Fluorescence microscope,
Tokyo, Japan) equipped with a triple-bandpass filter to visualize
simultaneously DAPI, spectrum-green and spectrum-orange.
Cut-off levels for the definition of aneuploidy were derived
from experiments with normal human peripheral blood and bone
marrow cells. Tumours exhibiting deletions or loss of the p53
allele in fewer than 10% of cells were not regarded as being
deleted for the p53 gene (cut-off). At least 100 tumour cell nuclei
were counted per sample.
Immunohistochemistry
The avidin–biotin immunohistochemistry was performed by stan-
dard methods. In brief, 5-mm-thick sections of paraffin-embedded
tissues of nine metastatic MM (ME 3 to 11) were cut and placed on
positively charged microscope slides (Probe on Plus, Fisher
Scientific Company, Pittsburgh, PA, USA). Sections were deparaf-
finized and antigen retrieval was performed by microwave heating
in citrate buffer. Endogenous peroxidase activity was blocked with
3% hydrogen peroxide in methanol for 30 min. Before staining,
sections were exposed to 2% normal goat serum. The sections
were incubated with the primary antibody DO7 (Dako,
Carpinteria, CA, USA; murine IgG2b) at a dilution of 1:200 for 1 h
at room temperature followed by an incubation with a biotinylated
goat antimouse antibody (Dako, LSAB 2 kit) for 30 min.
Peroxidase-labelled streptavidin was added for 30 min (Dako,
LSAB 2 kit). The reaction product was developed using
aminoethylcarbazole (Dako, AEC substrate system) and the bright
red-stained immunoreactive sites could easily be distinguished
from the melanin pigment. The sections were briefly counter-
stained with Mayer’s haematoxylin. Negative controls included
species and isotype-matched antibodies (mouse IgG2b, Dako) and
positive controls with anti-S 100 antibody (Dako) were performed
on all specimens.
Tumours of the human melanoma cell line 518A2 grown in
severe combined immunodeficient (SCID) mice were used as
additional positive control for p53 staining. This cell line has a p53
mutation and the protein can be detected in vitro and in vivo by
Western blot and immunohistochemistry.
Only specimens with nuclear labelling and staining of more than
1% of the cells examined were considered to be positive for p53




The composite karyotypes of eight analysable metastatic MM (ME
1, 2, 4, 5, 7, 8, 10, 11) are shown in Table 2 and demonstrate a
non-random pattern of karyotypic aberrations in advanced MM.
According to our data, aberrations of chromosomes 1 and 9 were
most frequently observed. Both chromosomes were involved in
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Table 2 Cytogenetic analysis of eight cases of MM. ME 3, ME 6 and ME 9 were not evaluable by karyotype analysis
Case Results
ME 1 54–64, XXXY, +der(1)t(1;10)(p33;p12), +i(lq), +der(2)t(2;6)(p21;q14), +i(2q),
+del(3)(q24)´2, +4, t(7;22)(p12;p11), +8, +8, +del(9)(p21), –10, +11, –12, +13,
+13, +18, +21, +22, +22[cp6]
ME 2 45, XX, del(1)(p33), dup (1)(p22p33), del(9)(q33), del(12)(p12), –13,
t(17;?)(p12;?), –19, –21, M(1)[cp2]
ME 3 Not analysable
ME 4 46, XX [4]/43–47, XX, del(1)(p22), del(2)(p16p22), –5, del(5)(q12q14), +6, –7,
del(7)(p12p21), i(8q), del(10)(p12), –11, t(15;15)(q10;q10), del(17)(p13), –19, –20,
–22 [cp10]
ME 5 52–75, XXYY or del(X)(q22q25), +1, del(2)t(2;?)(q35;?), +del(3)(q21q31), –5 or
del(5)(q15q23), +del(7)(p12p14)´2, +8, del(9)(p21)´2, del(10)(p13), –12, –15,
del(17)(p13), +18, +19, i(20p) [cp 10]
ME 6 Not analysable
ME 7 73–78, XXXY, +del(1)q32), del(2)p21), +3 or +der(3)t(3;?)(q26;?), –4´2,
+t(4;5)(q13;q12)´2, +der(8)t(8;?)(p21;?)´3, del(9)(p21)´2, –10 or del(10)(p13),
–11, +12, t(13;14)(q10;q10), +15, t(15;15)(q25;q13), +16, del(17)(p13) or
del(17)(p11), –21, del(22)(q12) [cp 7]
ME 8 46, XY [cp 5]/46, XY, del(9)(p21) [cp 7]
ME 9 Not analysable
ME 10 41–42, X, –Y, –4, –6, –9, –10, –14, hsr (4) ´2 [cp3]
78–82, XY, –3´2, –4, del(6)(q22), –9, del(9)(p21), –10 ´3, del(11)(q23), –12 ´3,
–14, del(17)(p13), –21, hsr (4) [cp 3]
ME 11 65–78, XX or XY or XXY, dir dup (1)(p21–>pter), del(2)(p21) or del(2)(p16) or
del(2)(p22), +3´2, –4, +del(6)(q15q24), +7´2, +del(8)(p21)´2, der(9)(9q22–>
qter::9qter–>q22::9q22–>qter), +del(9)(p21), –11, +11p, –12, t(14;14)(q23;q21) or
+t(14;15)(p10;q10), –15, del(16)(p12)´2, –17, del(17)(p11), +19, +20, +22, [cp6]134 I Okamoto et al
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Figure 1 A representative R-banded karyotype of ME 7 is shown. The breakpoint on chromosome 17 is in this case located on 17p11. The complete
karyogram of this hypertriploid cell reads as follows: 75, XXXY, +t(X;12)(p10;q10), +del(1)(p32), +del(1)(p22), t(1;11)(q12;q25), –4, +del(5)(q11q13),
der(6)t(6;?)(p12;?), +del(7)(p21), +der(8)t(8;?)(p22;?)´2, –9, +del(10)(p11), der(?10)t(?10;16)(p10;q10), t(12;18)(q21;q21), –14, del(17)(p11), +18, –19, +20,
–21, t(20;21)(q12;p13), –22seven of eight analysable melanomas, followed by chromosomes 8
and 17 involved in six and chromosomes 2 and 12 in five tumours
each. The X chromosomes were affected in two cases. No abnor-
malities in Y chromosomes could be detected.
The most common change was a deletion of the band p21 on
chromosome 9 in six MM, where the putative tumour-suppressor
gene MTS-1, encoding for the cyclin-dependent kinase inhibitor 2, is
located. Next in terms of frequency was the deletion of 17p13 in
four MM (ME 4, 5, 7 and 10). Adding one patient with a deletion on
17p11 of ME 11 and the unbalanced translocation t(17;?)(p12;?) of
ME 2 together with del(17)(p13), six melanomas showed deletions
of the region 17p11–13 by using karyotype analysis (Figure 1). The
breakpoints of all these deletions were proximal to the p53-TSG
locus 17p13.1. Extending these findings we used FISH to confirm
the frequency of the deletions of p53-TSG locus in MM.
FISH
Eight MM (ME 1, 2, 4, 5, 7, 9, 10, 11) were analysable with FISH.
Three MM (ME 2, 7 and 10) showed mono-allelic deletions of the
p53-TSG locus (cells with 0–1 p53 signals). Simultaneously, a
gain of chromosome 17 centromere signals (C17-s) up to eight
signals was found in these cases. In tumour ME 2 16.82% of the
cells were found to have no or one signal for the p53-TSG locus
(p53-s), and a further 7.54% of the cells showed fewer p53 signals
than C17-s (see Table 3). For ME 7 26.73% of the cells were seen
to be monozygous for p53-s, whereas a further 57.44% showed
less p53-TSG-s than C17-s compatible with an imbalance. Finally,
26.73% of the cells of ME 10 were found to be monozygous for
the p53-TSG locus and another 48.52% of the cells showed less
p53-s than C17-s.
Four other cases, namely ME 4, 5, 9 and 11, did not show mono-
allelic deletions but polysomic tumour cells with imbalances
leading to less p53-s than C17-s in a significant proportion of
nuclei. The exact percentages of cells with imbalances of p53-s to
C17-s are given in Table 3.
No MMs except case ME 6 were found to overexpress p53
protein as determined by immunohistochemistry. In case ME 6,
13% of the cells examined were positive for p53 protein but
neither cytogenetic nor FISH data could be obtained.
17p11–13 deletions in advanced MM 135
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Table 3 FISH data shown as a percentage
%
Case n (p53) = n (#17) n (p53) = 0–1 n (#17) > n (p53) Cells evaluated
ME 1 88, 12 0 7, 92 101
ME 2 74, 71 16, 82 24, 36 107
ME 3 – – – 0
ME 4 70, 59 0, 98 20, 59 102
ME 5 26, 67 10, 48 73, 33 105
ME 6 – – – 0
ME 7 16, 83 26, 73 84, 17 101
ME 8 – – – 0
ME 9 64, 08 1, 94 35, 92 103
ME 10 24, 75 26, 73 75, 25 101
ME 11 67 1 31 100
n(p53), number of p53 signals, n(#17): number of centromeres of chromosome 17
Table 4 Results of karyotypic analysis (metaphase cytogenetics), FISH and immunohistochemistry
Case KA data FISH data Immunohistochemistry
Deletions Addition
(%) (%)
ME 1 – 7, 92 3, 96 Not detected
ME 2 t(17;?)(p12;?) 24, 36 0, 93 Not detected
ME 4 del(17)(p13) 20, 59 8, 82 < 1% positive cells
ME 5 –17[2c], del(17)(p13) 73, 33 0 < 1% positive cells
ME 7 del(17)(p13) or 84, 17 0 < 1% positive cells
del(17)(p11)
ME 8 – Not detectable Not detectable < 1% positive cells
ME 9 Not detectable 35, 92 0 < 1% positive cells
ME 10 del(17)(p13) 75, 25 0 < 1% positive cells
ME 11 –17, del(17)(p11) 31 2 < 1% positive cells
For karyotype analysis, only chromosomal aberrations of chromosome 17 are shown. The numbers of the column ‘FISH data’ are values in per cent of nuclei
with deletions or additions. Melanomas that were not detectable either with karyotyping or with FISH (ME 3 and 6) are excluded from this table. –, detectable,
but no aberration on chromosome 17 could be observed; [2c], in two cells.DISCUSSION
The cytogenetic and FISH data obtained in this study provide
evidence that the deletion of chromosomal material of the region
17p11–13 is a frequent event in metastatic MM. According to our
FISH data, three of eight analysable MM had clones with no or
only one p53-TSG allele and an additional four MMs showed
fewer signals of the p53-TSG locus than of the centromere of
chromosome 17. Immunohistochemical investigation of nine
MMs (ME 3-ME 11) showed that only one specimen overex-
pressed p53 protein. These observations are in concordance with
our cytogenetic results, which demonstrate for the first time that
loss of the p53-TSG alleles may be responsible for the reduced
expression of the p53-TSG in metastatic MM and may therefore
be associated with progression of this disease.
We observed good correlations between FISH and conventional
cytogenetic methods. Eight of 11 MMs could be investigated with
each method (karyotype analysis and FISH). Applying both
methods together, information on nine MMs could be obtained.
Correlation of karyotype and FISH data could be observed in
seven of nine cases (see Table 4).
p53 inactivation caused by p53 point mutations has been
demonstrated in haematological malignancies such as in acute
myelogenous leukaemia (AML) and chronic myelogenous
leukaemia (CML) blast crisis (Gaidano et al, 1993) as well as in
solid tumours such as malignant gliomas (Frankel et al, 1992),
medulloblastomas (Saylors et al, 1991) colon, oesophageal squa-
mous cell, pancreatic, hepatic carcinoma and other tumours of the
brain, lung, breast and ovary (Prives and Manfredi, 1993; Lee et
al, 1994). In carcinomas, most of the mutations (75–80%) are
missense mutations producing a faulty protein and the second
allele in these cells is then lost (Carder et al, 1993; Levine, 1993).
Therefore, we conclude that in the case of a deletion of a p53-TSG
allele in metastatic MM, the remaining p53-TSG might be inacti-
vated by mutations that are not detectable with immunohistochem-
istry, FISH or conventional cytogenetics.
As far as the expression of p53-TSG in metastatic MM is
concerned, contradictory results have been reported in the past. In
contrast to studies reporting that an elevated rate of p53 expression
could be observed in metastatic MM (Saylors et al, 1991; Kanoko
et al, 1995; Poremba et al, 1995), which may indirectly reflect p53
gene mutations, we could not confirm this phenomenon. However,
we frequently detected cytogenetic loss of the 17p11–13 region.
This genetic alteration may lead to loss of p53 function or
decreased p53 expression, which could be confirmed by immuno-
histochemistry in our study.
The deletion of band p21 on chromosome 9, also found by
others, appears to be the most frequent aberration in our study
(Cannan-Albright et al, 1992; Fountain et al, 1992; Lynch et al,
1993; Holland et al, 1994; Skolnick et al, 1994). The deletion of
9p21, the location of MTS-1 (CDKN-2, p16) and possibly further
tumour-suppressor genes, was found in 57 of 99 melanoma cell
lines (Cannan-Albright et al, 1992). MTS-1 (and other genes on
this region) have therefore been suspected to be factors respon-
sible for both susceptibility and progression to MM (Saylors et al,
1991; Stretch et al, 1991).
Chromosomal and genetic deletions have been observed
frequently in human tumours, and recurrently deleted gene regions
136 I Okamoto et al
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Figure 2 FISH feature of ME 4, showing two aneuploid melanoma cells with five signals for the centromere of chromosome 17 (green signals) and three
signals for the p53-TSG locus (red signals). Melanoma cells are surrounded by four lymphocytes displaying a normal hybridization pattern (two signals with both
probes). Nuclei were counterstained with DAPIhave become of special interest. Our findings may shed new light
on the potential significance of the tumour-suppressor gene p53 in
the tumour biology of MM.
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